Related Articles
Secondary resistance to imatinib in patients with gastrointestinal stromal tumors through an acquired KIT exon 17 mutation
Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours
Expression of stem cell factor in gastrointestinal stromal tumors: Implications for proliferation and imatinib resistance
Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines
Molecular characterisation of gastrointestinal stromal tumours in a South African population